Lyell Immunopharma Valuation Multiples

Lyell Immunopharma Overview

About Lyell Immunopharma

Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.

Founded

2018

HQ

Employees

300

Website

lyell.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $32K

EBITDA: ($248M)

EV

$228M

Valuation Multiples

Multiples.vc

Start free trial

Lyell Immunopharma Financials

Lyell Immunopharma reported last 12-month revenue of $32K and negative EBITDA of ($248M).

In the same LTM period, Lyell Immunopharma generated ($248M) in EBITDA losses and had net loss of ($261M).

Lyell Immunopharma P&L

In the most recent fiscal year, Lyell Immunopharma reported revenue of $36K and EBITDA of ($190M).

Lyell Immunopharma expects next 12-month revenue of XXX and NTM EBITDA of XXX

Lyell Immunopharma Stock Performance

Lyell Immunopharma has current market cap of $503M, and enterprise value of $228M.

Lyell Immunopharma's stock price is $23.70.

Lyell Immunopharma Valuation Multiples

Lyell Immunopharma trades at 7210.5x EV/Revenue multiple, and (0.9x) EV/EBITDA.

Lyell Immunopharma Financial Valuation Multiples

As of March 18, 2026, Lyell Immunopharma has market cap of $503M and EV of $228M.

Equity research analysts estimate Lyell Immunopharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Lyell Immunopharma has a P/E ratio of (1.9x).

Lyell Immunopharma Margins & Growth Rates

Lyell Immunopharma's revenue in the last 12 month grew by 1614%.

Lyell Immunopharma's revenue per employee in the last FY averaged $0.0M.

Lyell Immunopharma's rule of 40 is (783076%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Lyell Immunopharma's rule of X is (780655%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Lyell Immunopharma Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Lyell Immunopharma M&A Activity

Lyell Immunopharma acquired XXX companies to date.

Last acquisition by Lyell Immunopharma was on XXXXXXXX, XXXXX. Lyell Immunopharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Lyell Immunopharma Investment Activity

Lyell Immunopharma invested in XXX companies to date.

Lyell Immunopharma made its latest investment on XXXXXXXX, XXXXX. Lyell Immunopharma invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).